Omalizumab in the treatment of various forms of chronic urticaria

BACKGROUND: Chronic urticaria is a skin disease characterized by the appearance of itchy weals and/or angioedema for 6 or more weeks. subdivided into chronic spontaneous urticaria, which occurs due to an unknown cause, and inducible as result exposure various physical factors (water, cold, heat, pressure, mechanical irritation), can occur simultaneously independently each other. Omalizumab, anti-IgE monoclonal antibody, approved treatment patients with second choice in cases resistance antihistamine treatment. In combination effectiveness omalizumab has been little studied.
 AIM: compare induced urticaria.
 MATERIALS AND METHODS: Under supervision there were 30 combined (15 group). Evaluation was carried out according results questionnaires DLQI (dermatological index quality life), CU-Q2oL (questionnaire life urticaria), UCT (urticaria control test), UAS activity scale), HADS (Hospital Anxiety Depression Scale) provocation tests dynamics before during treatment.
 RESULTS: All received 300 mg subcutaneously once month 12 months. After first injection omalizumab, we noted decrease severity increase level when comparing parameters than 90% patients. Improved performance remained at this throughout all subsequent months CONCLUSION: Omalizumab equally effective isolated form urticaria. The use allows you symptoms even prolonged use.